Your neuropsych research just got 5x faster. Track actual Alzheimer's progression across 439,000 patients. Link MDD outcomes to claims for 2.7M patients. Get longitudinal analyses in 15 seconds instead of waiting weeks.

With NeuroBlu Analytics v4.19, we are proud to deliver the most transformative dataset release in our history. The 25R3 dataset establishes NeuroBlu as the market leader in neuropsychiatric research, with unmatched scale, depth, and analytic capabilities.

This release strengthens our support for organizations working across the pharma value chain, from enterprise RWD teams with claims integration needs to clinical development teams expanding into neurology. With 36.2M patients, instant longitudinal analysis, and a claims-ready infrastructure, NeuroBlu now sets the standard for integrated psychiatric, neurological, and physical health research.

‍

25R3 Dataset: Unmatched Neuropsychiatric Depth

The 25R3 update expands coverage across psychiatric and neurological conditions, bringing richer longitudinal views and integrated physical health data.

Core Statistics:

• 36.2M total patients, current as of August 2025
• 15M active patients with encounters in the last 12 months
• 32.4M patients with integrated physical health content
• 16.7M patients with 17,909 distinct lab concepts
• 68.75% of patients with two or more visits

This unparalleled scale creates the foundation for precise, real-world evidence across psychiatry and neurology.

‍

Neuropsychiatric Leadership: Expanded Clinical & Therapeutic Coverage

Alzheimer’s Disease

• 439k+ patients with Alzheimer’s diagnosis, plus 15k+ tracked from MCI to AD
• Rich cognitive assessments: MSE, MiniCog, MoCA, MMSE
• Mean follow-up: 4.3 years, with 50% of patients tracked between 1.7 and 6.4 years
• Cohort demographics: 65% female, mean age 76.8 at first visit

Major Depressive Disorder

• 2.7M+ patients with MDD diagnoses
• 4.3M with PHQ-9 scores, 3.8M with PHQ-2
• NLP-enhanced extraction for suicidal ideation and anhedonia
• Mean follow-up: 4.5 years, with 50% tracked between 2.1 and 6.7 years

Schizophrenia

• 370k+ patients with schizophrenia spectrum disorders
• 69k+ patients with MSE data, 20k+ with AIMS
• Rich specialty measures: BNSA, PSRS, and symptom-specific tracking
• Mean follow-up: 4.2 years, with 50% tracked between 1.7 and 6.6 years

‍

Linking-Ready Infrastructure with Medication & Dosing Insights

The 25R3 architecture introduces Datavant-ready temporal alignment, enabling linkage to claims data for cost-effectiveness and burden-of-illness studies.

Key Capabilities:

• Support for 4 initial partners (expanding to 9 by 25R4)
• Exact timing for comparative effectiveness and HEOR studies
• New medication detail fields: dose, frequency, and units
• Support for treatment adherence, intensity, and real-world dosing analysis

With these upgrades, researchers can directly connect clinical progression to economic outcomes.

‍

On-Demand Longitudinal Analysis in Descriptive Stats

NeuroBlu v4.19 introduces real-time longitudinal analysis in Cohort Explorer, eliminating the need for manual, week-long queries.

Instant insights include:

• Number of patients with 5+ or 7+ years of data
• Progression tracking across multiple hospitalizations
• MCI to AD conversion timelines
• Treatment duration and remission/relapse trajectories

These capabilities empower faster exploration of patient journeys in across neuropsychiatry including MDD, schizophrenia, and Alzheimer’s disease.

With the release of v4.19 and the 25R3 dataset, NeuroBlu has reached a new level of scale, depth, and usability. From detailed dosing insights to instant longitudinal analysis and claims-ready integration, this release positions NeuroBlu as the definitive platform for real-world evidence in neuropsychiatry and beyond.

See your Alzheimer's cohort in 30 minutes. Schedule a demo. Contact us to schedule a demo.

Already a customer? Log in here.

‍